An editorial suggests these findings may not have a significant impact on the care of the many patients with diabetes and hypertension who do not have chronic kidney disease and proteinuria, because many of these patients already have other compelling indications for RAS blockers; and most will need at least two or three agents for good blood pressure control, so it probably does not matter which agent is started first. It notes that given the abysmal rates of blood pressure control in this high risk population and given all of the synthesised evidence already available, perhaps less time and fewer resources should be spent being distracted by which specific drug to use first, and the focus instead should be on treating these high risk patients.